Mi­rati preps its first look at their KRAS G12C con­tender, and they have to clear a high bar for suc­cess

If you’re a big KRAS G12C fan, mark your cal­en­dars for Oc­to­ber 28 at 4:20 pm EDT.

That’s when Mi­rati $MRTX will un­veil its first peek at the ear­ly clin­i­cal da­ta avail­able on MRTX849 in pre­sen­ta­tions at the AACR-NCI-EORTC In­ter­na­tion­al Con­fer­ence on Mol­e­c­u­lar Tar­gets and Can­cer Ther­a­peu­tics in Boston.

Mi­rati has been ex­pe­ri­enc­ing the full ef­fect of a ri­val’s ini­tial suc­cess at tar­get­ing the G12C pock­et found on KRAS, of­fer­ing the biotech some sup­port on the con­cept they’re af­ter — and biotech fans a race to the top. Am­gen made a big splash with its first pos­i­tive snap­shot on lung can­cer, but de­flat­ed sky-high ex­pec­ta­tions as it proved hard­er to find sim­i­lar ben­e­fits in oth­er types of can­cers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.